

Johanne I Weberpals

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2564799/publications.pdf>

Version: 2024-02-01

31
papers

2,086
citations

567281

15
h-index

526287

27
g-index

31
all docs

31
docs citations

31
times ranked

3366
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 5579-5579.	1.6	0
2	Outcomes of recurrent and metastatic endometrial cancer (RMEC) treated with systemic progestins.. Journal of Clinical Oncology, 2022, 40, 5585-5585.	1.6	1
3	Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency.. Journal of Clinical Oncology, 2022, 40, 5544-5544.	1.6	0
4	Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. Cancer Medicine, 2021, 10, 3045-3058.	2.8	11
5	Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).. Journal of Clinical Oncology, 2021, 39, 5537-5537.	1.6	0
6	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer, 2021, 31, 949-958.	2.5	7
7	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Medicine, 2021, 10, 7162-7173.	2.8	4
8	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. JAMA Oncology, 2021, 7, 1772.	7.1	44
9	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer, 2021, 125, 1666-1676.	6.4	18
10	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of Clinical Oncology, 2020, 38, 3494-3505.	1.6	28
11	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecologic Oncology, 2020, 159, 101-111.	1.4	14
12	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 4767-4776.	7.0	68
13	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 710-722.	10.7	70
14	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.. Journal of Clinical Oncology, 2020, 38, 6057-6057.	1.6	7
15	Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.. Journal of Clinical Oncology, 2019, 37, 5522-5522.	1.6	3
16	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncology, 2018, 4, e173776.	7.1	116
17	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clinical Cancer Research, 2018, 24, 6168-6174.	7.0	44
18	Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.. Journal of Clinical Oncology, 2018, 36, 5537-5537.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.. Journal of Clinical Oncology, 2018, 36, 5545-5545.	1.6	2
20	Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients.. Journal of Clinical Oncology, 2018, 36, 5561-5561.	1.6	2
21	Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. Clinical Cancer Research, 2017, 23, 4501-4510.	7.0	45
22	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	13.7	1,261
23	Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial.. Journal of Clinical Oncology, 2017, 35, TPS5608-TPS5608.	1.6	2
24	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. Journal of Translational Medicine, 2016, 14, 83.	4.4	18
25	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology, 2015, 137, 216-222.	1.4	65
26	Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 2559-2571.	4.1	22
27	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genetics, 2011, 204, 525-535.	0.4	49
28	The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. Cancer Cell International, 2011, 11, 29.	4.1	20
29	The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. International Journal of Cancer, 2009, 124, 806-815.	5.1	88
30	Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway. Journal of Clinical Oncology, 2008, 26, 3259-3267.	1.6	61
31	A Rare Case of Ectopic Adrenocorticotrophic Hormone Syndrome in Small Cell Carcinoma of the Vagina. Journal of Lower Genital Tract Disease, 2008, 12, 140-145.	1.9	14